Perrigo Company plc PRGO
- Market cap
- $2.1B
- P/E
- 0.0×
Follow PRGO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.72 | 63.68 | 36.28 | 38.38 | 40.01 | 35.34 | 30.78 | 26.81 | 23.89 | 12.17 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 152.36 | 91.73 | 95.93 | 57.50 | 63.86 | 50.90 | 43.90 | 40.28 | 34.60 | 30.93 |
High Price
|
|||
| 12,800 | 10,400 | 10,600 | 11,200 | 11,500 | 9,900 | 8,900 | 9,140 | 8,379 | 8,100 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 5,281 | 4,946 | 4,732 | 3,870 | 4,088 | 4,139 | 4,452 | 4,656 | 4,373 | 4,253 |
Revenue
|
|||
| 38.86% | 40.02% | 38.71% | 37.05% | 36.57% | 34.22% | 32.69% | 36.09% | 35.27% | 35.14% |
Gross Margin
|
|||
| (4,848) | 280 | 291 | 148 | 6 | 259 | (139) | (8) | (81) | (1,298) |
EBT
|
|||
| (91.81%) | 5.66% | 6.14% | 3.82% | 0.14% | 6.25% | (3.12%) | (0.18%) | (1.85%) | (30.52%) |
EBT Margin
|
|||
| (4,013) | 120 | 131 | 146 | (163) | (69) | (141) | (13) | (172) | (1,425) |
Net Income
|
|||
| 432 | 422 | 416 | 392 | 382 | 308 | 338 | 362 | 335 | 347 |
Depreciation
|
|||
| 36.85 | 34.76 | 34.34 | 28.46 | 30.04 | 30.98 | 33.10 | 34.41 | 31.83 | 30.71 |
Revenue/Sh
|
|||
| (28.01) | 0.84 | 0.95 | 1.07 | (1.19) | (0.52) | (1.04) | (0.09) | (1.25) | (10.29) |
Earnings/Sh
|
|||
| 4.57 | 4.91 | 4.30 | 2.85 | 4.67 | 1.17 | 2.28 | 3.00 | 2.64 | 1.72 |
Cash Flow/Sh
|
|||
| 1.73 | (0.01) | (0.65) | (0.99) | (1.22) | (1.11) | (0.50) | (0.57) | (0.55) | (0.63) |
Capex/Sh
|
|||
| 6.30 | 4.90 | 3.66 | 1.86 | 3.45 | 0.06 | 1.78 | 2.42 | 2.09 | 1.09 |
Free CF/Sh
|
|||
| 41.57 | 43.36 | 41.13 | 42.68 | 41.55 | 38.56 | 36.00 | 35.24 | 31.44 | 21.19 |
Book Value/Sh
|
|||
| 143 | 142 | 138 | 136 | 136 | 134 | 135 | 135 | 137 | 139 |
Shares
|
|||
| 0.00 | 106.77 | 41.22 | 47.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 2.35 | 2.58 | 1.13 | 1.82 | 1.49 | 1.26 | 1.06 | 0.96 | 0.81 | 0.45 |
PS Ratio
|
|||
| 2.08 | 2.07 | 0.94 | 1.21 | 1.08 | 1.01 | 0.98 | 0.94 | 0.82 | 0.66 |
PB Ratio
|
|||
| 3.33 | 3.12 | 1.70 | 2.59 | 2.21 | 1.66 | 1.85 | 1.68 | 1.51 | 1.18 |
EV/Sales
|
|||
| 19.47 | 22.11 | 15.93 | 39.69 | 19.20 | 856.58 | 34.38 | 23.81 | 22.91 | 32.83 |
EV/FCF
|
|||
| 655 | 699 | 593 | 388 | 636 | 156 | 307 | 406 | 363 | 239 |
Op' Cash Flow
|
|||
| 248 | (1) | (89) | (135) | (166) | (148) | (68) | (77) | (75) | (88) |
Capex
|
|||
| 902 | 698 | 504 | 253 | 470 | 8 | 240 | 328 | 288 | 151 |
FCF
|
|||
| 969 | 1,384 | 1,365 | 1,395 | 1,752 | 2,272 | 1,606 | 1,247 | 1,438 | 1,785 |
Working Cap'
|
|||
| 5,797 | 3,341 | 3,242 | 3,369 | 3,565 | 3,521 | 4,107 | 4,073 | 3,618 | 3,640 |
Total Debt
|
|||
| 5,175 | 2,663 | 2,691 | 3,015 | 2,933 | 1,656 | 3,506 | 3,322 | 3,059 | 3,109 |
Net Debt
|
|||
| 5,958 | 6,171 | 5,668 | 5,804 | 5,655 | 5,152 | 4,842 | 4,768 | 4,319 | 2,936 |
Sh' Equity
|
|||
| (24.16%) | 0.94% | 1.16% | 1.31% | (1.43%) | (0.63%) | (1.31%) | (0.12%) | (1.68%) | (15.68%) |
ROA
|
|||
| (11.23%) | 4.23% | 1.77% | 1.24% | 1.93% | 3.77% | 0.59% | 1.17% | 0.96% | (11.60%) |
ROIC
|
|||
| (49.96%) | 1.97% | 2.21% | 2.55% | (2.84%) | (1.28%) | (2.81%) | (0.26%) | (3.78%) | (39.29%) |
ROE
|
|||
Perrigo Company plc peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PBH Prestige Consumer Healthcare Inc. | $2.2B | 13.0× | Compare |
| BCRX BioCryst Pharmaceuticals, Inc. | $2.2B | 0.0× | Compare |
| ALVO Alvotech | $2.3B | 0.0× | Compare |
| HCM HUTCHMED (China) Limited Sponsored ADR | $2.4B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ETON Eton Pharmaceuticals, Inc. | $1.7B | 123× | Compare |
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 15.3× | Compare |
| SUPN Supernus Pharmaceuticals, Inc. | $2.5B | 0.0× | Compare |
| XERS Xeris Biopharma Holdings, Inc. | $1.6B | 0.0× | Compare |
Perrigo Company plc (PRGO) key facts
- Perrigo Company plc (PRGO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on the New York Stock Exchange.
- Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Perrigo Company plc reported a net loss of $1.4 billion, or a loss of $10.29 per share, for fiscal 2025.
- As of September 25, 2026, PRGO traded at $15.42, a market capitalization of $2.1 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.5× sales.
- Perrigo Company plc pays an annual dividend of $1.08 per share, a yield of 3.42%.
- Return on equity was −39.3% and debt-to-equity 1.31.
Perrigo Company plc (PRGO) Latest News
25 Sep
Perrigo shares jumped 6.1% to $14.68 on heavy volume after advancing on progress under its Three-S strategy: Stabilize, Streamline and Strengthen. The stock rebounded after a four-week slide of 6.2% as investor confidence grows in portfolio simplification through divestitures, notably Dermacosmetics, with proceeds earmarked to reduce debt and strengthen the balance sheet. Perrigo says market-share gains in U.S. store-brand OTC products and in key European brands are strengthening its core business. The company reiterated its 2026 guidance with expectations of a stronger second half. Ahead of the next quarterly report, consensus estimates are EPS of $0.57 and revenue of about $994.7 million, down 28.8% and 4.7% year over year, respectively. Analysts note that revisions to earnings estimates have been trending lower, providing a mixed signal for near-term momentum. Three-S initiatives and debt reduction improve longer-term prospects, but lower short-term earnings revisions cap upside.
12 Aug
Perrigo (PRGO) released its Q2 2026 earnings call transcript detailing financial results, segment performance, and management outlook. Quarterly earnings transcript supplies updated financial metrics and guidance that can shift near-term investor sentiment and valuation.
9 Aug
Perrigo (PRGO) shares fell 62% and now trade at a discount. Large prior stock decline points to ongoing valuation pressure without altering core operations.
8 Aug
Perrigo Q2 earnings call highlights detail financial results, revenue trends and operational updates for the period. Q2 earnings details typically influence near-term sentiment and valuation without triggering major strategic changes.
Perrigo (PRGO) Q2 earnings beat revives the undervalued narrative for the stock. Q2 earnings beat revives undervalued perception but lacks indication of transformative shifts.
6 Aug
Perrigo Company plc (PRGO) stock surged 23% after Q2 earnings and sales beat estimates. Q2 earnings beat signals stronger financial performance with direct effect on near-term valuation.
5 Aug
Perrigo Company plc held its Q2 2026 earnings call covering revenue, earnings, segment performance and forward guidance. Quarterly earnings calls deliver updated financial metrics and outlook that moderately affect near-term stock sentiment.
Perrigo reported market share gains in Q2 2026 alongside declining sales during its earnings call. Mixed Q2 results indicate market share growth offset by sales decline with moderate effects on performance outlook.
Perrigo reports Q2 earnings with focus on key metrics. Q2 earnings release and metrics review can moderately affect financial outlook and investor views.
Perrigo Company plc reported second quarter 2026 financial results from continuing operations. Quarterly financial results supply performance metrics that can shift investor views and valuation.
9 Jun
Perrigo undergoes leadership shakeup, drawing focus to corporate governance and long-term strategy questions. Leadership transitions can affect governance perceptions and strategic priorities with moderate influence on operations and sentiment.
7 May
Perrigo (PRGO) reported weak Q1 results and lowered full-year guidance, raising concerns about its valuation and future performance amid challenges in sales and margins. Weak Q1 results and lowered guidance directly threaten Perrigo's financial trajectory and investor confidence.
Perrigo Company plc released Q1 2026 earnings call summary detailing quarterly financial results, guidance, and strategic updates. Q1 earnings call summaries disclose financial performance and forward guidance that significantly influence stock trajectory and investor sentiment.
Perrigo's Q1 earnings beat analyst estimates, but sales missed expectations, with both declining year-over-year. Earnings beat tempers negativity from sales miss and Y/Y declines, moderately affecting financial performance and investor sentiment.
6 May
Perrigo Company plc (PRGO) reported first-quarter earnings that beat analyst estimates, driven by strong performance in consumer self-care products and prescription pharmaceuticals. Beating Q1 earnings estimates signals robust financial performance and enhances investor sentiment toward PRGO's future growth.
Perrigo Company plc reported first quarter 2026 financial results from continuing operations. Quarterly earnings reports reveal key financial metrics that moderately influence PRGO's performance and investor sentiment.
5 May
Investors react to Perrigo's dermacosmetics unit sale, dividend payout, and ongoing strains in infant formula operations. Dermacosmetics divestiture refocuses strategy, dividend bolsters shareholder value, but infant formula strains threaten key revenue amid competitive pressures.
30 Apr
Perrigo Company plc completed the divestiture of its dermacosmetics business. Divestiture of non-core dermacosmetics unit streamlines operations and sharpens focus on primary healthcare portfolio.
1 Apr
Perrigo Company plc (PRGO) is positioned for growth amid market challenges. Growth positioning amid challenges moderately influences PRGO's financial performance and competitive outlook.
7 Mar
Perrigo (PRGO) shares dropped 18.9% after reporting a deeper net loss and issuing a weak 2026 outlook amid key operational changes. Deepening net loss and weak 2026 outlook drove an 18.9% stock plunge, likely significantly harming future financial performance and investor sentiment.
28 Feb
Perrigo Company plc (PRGO) released highlights from its Q4 earnings call, covering financial results, strategic updates, and forward guidance. Q4 earnings highlights detail financial performance and outlook, significantly impacting investor sentiment and stock trajectory.
27 Feb
Perrigo (PRGO) Q4 earnings missed estimates but sales beat expectations, with shares dropping after weak 2026 guidance. Earnings miss and weak 2026 outlook signal significant future financial challenges and negative investor sentiment.
26 Feb
Perrigo Company plc released Q4 2025 earnings call summary highlighting financial results, operational updates, and forward guidance. Q4 earnings call summaries detail financial performance and strategic outlook, significantly influencing stock trajectory and investor sentiment.
Perrigo Company plc's Q4 2025 earnings call highlights strategic navigation of challenges amid key financial results and forward guidance. Q4 2025 earnings call highlights strategic responses to challenges that could significantly alter Perrigo's trajectory and investor sentiment.
Perrigo (PRGO) Q4 earnings key metrics compared to Wall Street estimates, highlighting performance against analyst expectations. Q4 earnings beats or misses versus estimates significantly affect PRGO's stock price, investor sentiment, and short-term trajectory.
Perrigo Company plc (PRGO) released Q4 earnings snapshot, reporting key financial results for the quarter. Q4 earnings directly impact financial performance and investor sentiment for Perrigo.
Perrigo Company plc reported fourth quarter and fiscal year 2025 financial results from continuing operations. Quarterly and annual earnings reports drive significant shifts in investor sentiment and stock valuation.
Perrigo Company plc's Q4 earnings lagged behind analyst estimates. Q4 earnings missing estimates will moderately affect financial performance and investor sentiment.
25 Feb
Wall Street analysts unveil estimates for Perrigo (PRGO) Q4 outlook, detailing projections for key metrics. Wall Street Q4 estimates influence investor expectations and Perrigo's near-term financial performance outlook.
24 Feb
Wall Street analysts project 28.32% upside for Perrigo (PRGO) stock, questioning if it can realistically achieve this target amid current market conditions. Analyst consensus targets a 28.32% upside, likely influencing investor sentiment and short-to-medium term stock performance moderately.